Media stories about Spectranetics (NASDAQ:SPNC) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spectranetics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news headlines about the medical equipment provider an impact score of 46.1822479110041 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, Stifel Nicolaus lowered shares of Spectranetics from a “buy” rating to a “hold” rating and upped their target price for the stock from $34.00 to $38.50 in a research note on Wednesday, August 9th. Ten research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Spectranetics currently has a consensus rating of “Hold” and a consensus target price of $35.36.
Shares of Spectranetics (NASDAQ:SPNC) opened at $38.45 on Wednesday. The company has a current ratio of 1.92, a quick ratio of 1.43 and a debt-to-equity ratio of 7.61. Spectranetics has a one year low of $19.80 and a one year high of $38.55.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Spectranetics (SPNC) Share Price” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-spectranetics-spnc-share-price.html.
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.
Receive News & Ratings for Spectranetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics Corp and related companies with MarketBeat.com's FREE daily email newsletter.